Approval: The FDA granted traditional approval to encorafenib (Braftovi) in combination with cetuximab and chemotherapy for first-line BRAF V600E+ metastatic colorectal cancer.

Data: The Phase 3 BREAKWATER trial showed median OS of 30.3 months vs. 15.1 months for standard of care (HR 0.49; p<0.0001).

Funding: Secured a non-dilutive financing facility from Sixth Street to support the anticipated 2026 launch of risto-cel for Sickle Cell Disease. The facility includes $100M funded at close with up to $400M upon milestones.

Signal: Validates the "high-conviction" commercial model for base editing, providing massive runway without diluting equity at current valuations.

Data: Shares surged over 25% yesterday on Phase 3 SELVA success for its topical rapamycin gel (QTORIN) in microcystic lymphatic malformations.

Impact: The trial met its primary endpoint (p<0.001) with 95% of patients showing improvement. NDA submission is planned for H2 2026; if approved, it would be the first therapy for this condition.

Filing: Submitted a supplemental BLA for IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia (wAIHA), supported by Phase 2/3 ENERGY trial data.

Impact: If approved, it would be the first-ever treatment for this life-threatening autoantibody disease, utilizing the FcRn-blockade mechanism.

Data: Its KLRG1 antibody ulviprubart failed a pivotal MUSCLE study in inclusion body myositis (IBM), missing primary and key secondary endpoints. A prespecified subgroup in mild-to-moderate disease showed trends toward improvement.

Market Reaction: Shares cratered 80% yesterday after its Phase 3 PROSERA study of seralutinib in PAH failed to meet the prespecified statistical threshold (+13.3m vs. placebo in 6MWD; p=0.032 vs. required p<0.025).

Approval: Dupixent received its ninth FDA approval as the first and only medicine for allergic fungal rhinosinusitis (AFRS) in patients aged 6 and older. (Note: This approval arrived early, ahead of its scheduled Feb 28 PDUFA).

Data: Showed a 50% reduction in sinus opacification (vs. 10% for placebo) and a 92% reduction in the need for surgery or systemic steroids.

Spinoff: Launched its IPO roadshow for MiniMed, its diabetes spinoff, seeking to raise up to $784M at $25-$28 per share. The IPO is expected to price on March 5. Medtronic will retain a ~90% stake initially, with plans for full distribution within 12-15 months.

Strategy: Announced it is splitting its human health business into a distinct Oncology division and a separate Specialty/Pharma/Infectious Diseases unit—signaling intensified focus on the Keytruda franchise.

Policy: In a major policy change detailed in NEJM, FDA Commissioner Makary and Deputy Prasad announced the agency will now require only one rigorous clinical study as the default for new drug approvals.

Impact: This aims to accelerate access while leveraging modern confirmatory evidence standards, meaningfully compressing development timelines across the industry.

Appointments: Dr. Jay Bhattacharya took over as acting CDC Director, adding the role to his existing position as NIH Director. He replaces Jim O'Neill, signaling a "back-to-basics" focus on infectious disease monitoring.

Legislation: The Consolidated Appropriations Act, 2026 successfully extended Medicare telehealth coverage for two years, providing a $2.4B reimbursement floor for the digital health sector through 2028.